Ascentage 药
AAPG
15.37
+0.68
+4.63%
Ascentage 药
US · AAPG
#3045 按市值排名
上市于 2025
15.37
+0.68
+4.63%
实时 - 追踪5344个代码 - 心跳于17秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了6家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 29.21% +0.08pp
- 机构数量
- 54 -6
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund14.00%
Individual/Insider12.90%
Private Company10.44%
Public Company3.41%
Sovereign Wealth Fund1.30%
Other57.89%
主要股东 截至 2026-04-20
Takeda Pharmaceuticals International AG
6.61% · 6.08M 股
Dajun Yang
6.32% · 5.81M 股
HealthQuest Pharma Limited
3.83% · 3.52M 股
Ming Guo
3.60% · 3.31M 股
Vanguard Capital Management, LLC
3.19% · 2.93M 股
China Universal Asset Management Company Ltd.
2.96% · 2.72M 股
Shaomeng Wang
2.73% · 2.51M 股
Morgan Stanley
1.73% · 1.59M 股
JPMorgan Chase & Co.
1.69% · 1.55M 股
BlackRock
1.46% · 1.34M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪34份申报 · 6次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Dajun Yang | Chairperson & CEO | 6.32% |
| Ming Guo | Co-Founder | 3.60% |
| Shaomeng Wang | Co-Founder, Chief Scientific Advisor & Non-Executive Director | 2.73% |
| Yifan Zhai | Chief Medical Officer | 0.11% |
| Thomas Knapp | General Counsel | 0.10% |
| Marc Lippman | Independent Non-Executive Director | 0.01% |
| Jin Cao | Head of Finance | 0.01% |
| David Sidransky | Independent Non-Executive Director | 0.01% |
| Wei Ren | Independent Non-Executive Director | 0.00% |
| Changqing Ye | Independent Non-Executive Director | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-05-20 | Yifan Zhai | Chief Medical Officer | Derivative Exercise and Retained | +92,746 | -- |
| 2026-05-20 | Dajun Yang | Chairperson & CEO | Derivative Exercise and Retained | +95,575 | -- |
| 2026-05-19 | Yifan Zhai | Chief Medical Officer | Other Derivative Acquisition | +616,546 | $6.58–8.12 |
| 2026-05-19 | Yifan Zhai | Chief Medical Officer | Other Derivative Acquisition | +804,880 | -- |
| 2026-05-19 | Dajun Yang | Chairperson & CEO | Other Derivative Acquisition | +616,546 | $6.58–8.12 |
| 2026-05-19 | Dajun Yang | Chairperson & CEO | Other Derivative Acquisition | +804,880 | -- |
| 2026-03-17 | Jiuyun Yu | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Marc Lippman | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Marina S. Bozilenko | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | David Sidransky | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Thomas Knapp | General Counsel | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Shaomeng Wang | Co-Founder, Chief Scientific Advisor & Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Yifan Zhai | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Changqing Ye | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Dazhong Lu | Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | HealthQuest Pharma Limited | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Dajun Yang | Chairperson & CEO | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Wei Ren | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Jin Cao | Head of Finance | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:29 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Ascentage 药 讨论区 0 条评论